Compare HTFL & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTFL | ALMR |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2025 | 2026 |
| Metric | HTFL | ALMR |
|---|---|---|
| Price | $57.56 | $31.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $50.50 | $35.40 |
| AVG Volume (30 Days) | ★ 1.3M | 699.1K |
| Earning Date | 11-12-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.37 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $176,034,000.00 | N/A |
| Revenue This Year | $41.24 | $59.79 |
| Revenue Next Year | $24.11 | $39.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.92 | N/A |
| 52 Week Low | $20.13 | $21.58 |
| 52 Week High | $57.74 | $39.61 |
| Indicator | HTFL | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 69.75 | 55.28 |
| Support Level | $46.46 | $23.52 |
| Resistance Level | N/A | $38.64 |
| Average True Range (ATR) | 2.89 | 2.46 |
| MACD | 0.64 | 0.55 |
| Stochastic Oscillator | 90.75 | 100.00 |
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.